Two Maryland biotechs announced inroads in their efforts to develop stem cell treatments for depression and diabetes.
Neuralstem has gotten the regulatory go-ahead to advance to phase 1b in its ongoing clinical trial of its stem cell treatment for major depressive disorder.
NSI-189 stimulates new neuron growth in the brain’s hippocampus, which may be involved in depression and other conditions, including Alzheimer's disease and post-traumatic stress disorder, according to the Rockville biotech.
To read the full, original article click on this link: Gazette.Net: Maryland stem cell companies advance therapies for diabetes, depression
